Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Prior treatment

• 1\. Patients with contraindications specified in the drug instructions for the targeted drugs involved in the corresponding organoid drug sensitivity tests.

Other illness

• 3\. Patients with severe organ dysfunction, metabolic diseases, or other conditions significantly affecting survival.
• 4\. Other active malignant disease requiring therapy.

Other

• 2\. Patients with incomplete clinical data.
• 5\. Females who are pregnant or breastfeeding.
• 5\. Patients without target lesions.
• 6\. Patients deemed unsuitable for inclusion by the researchers.

• 1\. Adult participants who have either been initially diagnosed with locally advanced thyroid cancer or have experienced persistent or recurrent thyroid cancer, including cervical nodal recurrence. Types of pathology include:
  • Papillary thyroid carcinoma (PTC)
  • Follicular thyroid carcinoma (FTC)
  • Medullary thyroid carcinoma (MTC)
  • Poorly differentiated thyroid carcinoma (PDTC)
  • Anaplastic thyroid carcinoma (ATC)
• 2\. Evidence of extrathyroidal extension and/or locally invasive disease and deemed at risk for R2 resection by treating team on clinical and/or fiberoptic examination and/or radiographic evaluation in the primary or recurrent setting. Evidence of "at risk for R2 resection" includes:
  • Vocal cord paralysis by fiberoptic examination
  • Extrathyroid and/or extranodal extension on CT or MRI, including tracheal and/or laryngeal cartilage invasion, esophageal involvement, and/or involvement of perithyroid muscles (e.g. strap, sternocleidomastoid, inferior constrictor muscles) or bone involvement
  • Extension into the mediastinum with visceral and/or vascular involvement
  • Involvement of the carotid artery or other major vessel by 180 degrees or more
  • Other factors that make the participant to be "at risk for R2 resection" may be allowed, after discussion with the study's principal investigator.
• 3\. There is at least one measurable lesion according to the Modified Response Evaluation Criteria in Solid Tumors (mRECIST).
• 4\. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2.
• 5\. Normal organ and bone marrow function.
• 6\. Adequate end-organ function (including bone marrow, coagulation, renal, liver and cardiac) 28 days prior to the study registration.
• 7\. Ability to swallow pills.
• 8\. Signed informed consent form.
• 9\. Expected survival time of more than 2 months.